Home    Back

Somavaratan (vrs-317)    (DrugBank: Somavaratan)

1 disease
IDDisease name (Link within this page)Number of trials
78Hypopituitarism12

78. Hypopituitarism    [ 462 clinical trials,   346 drugs,   (DrugBank: 45 drugs),   41 drug target genes,   80 drug target pathways]
Searched query = "Hypopituitarism", "Anterior pituitary hypothyroidism", "Syndrome of abnormal secretion of gonadotropin", "Hyposecretion of gonadotropins", "Adrenocorticotropic hormone deficiency", "ACTH deficiency", "Thyroid-stimulating hormone deficiency", "TSH deficiency", "Growth hormone deficiency", "GH deficiency", "GHD", "CGHD", "AGHD", "Prolactin deficiency", "PRL deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
12 / 462 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03145831
(ClinicalTrials.gov)		March 31, 20175/4/2017A Long-Term Safety Study of Somavaratan in Japanese Children With Growth Hormone DeficiencyAn Open-Label, Long-Term Safety Study of Long-acting Human Growth Hormone Somavaratan (VRS-317) in Japanese Children With Growth Hormone DeficiencyGrowth Hormone DeficiencyDrug: SomavaratanVersartis Inc.NULLTerminated3 YearsN/AAll21Phase 3United States;Japan
2EUCTR2016-002780-34-PL
(EUCTR)		30/01/201708/11/2016A Long-Acting Growth Hormone (Somavaratan, VRS-317) in ChildrenAn Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children with Growth Hormone DeficiencyThe VISTA Study: Versartis Long-Term Safety Study of Somavaratan Growth hormone deficiency
MedDRA version: 20.0;Level: PT;Classification code 10056438;Term: Growth hormone deficiency;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]		Product Name: Somavaratan
Product Code: VRS-317
INN or Proposed INN: VRS-317
Other descriptive name: VRS-317		Versartis, Inc.NULLNot RecruitingFemale: yes
Male: yes		400Phase 3United States;Canada;Belgium;Poland;Sweden
3EUCTR2016-002780-34-BE
(EUCTR)		16/12/201619/09/2016A Long-Acting Growth Hormone (Somavaratan, VRS-317) in ChildrenAn Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children with Growth Hormone DeficiencyThe VISTA Study: Versartis Long-Term Safety Study of Somavaratan Growth hormone deficiency
MedDRA version: 19.0;Level: PT;Classification code 10056438;Term: Growth hormone deficiency;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]		Product Name: Somavaratan
Product Code: VRS-317
INN or Proposed INN: VRS-317
Other descriptive name: VRS-317		Versartis, Inc.NULLNot RecruitingFemale: yes
Male: yes		300Phase 3United States;Canada;Poland;Belgium;Sweden
4EUCTR2016-002780-34-SE
(EUCTR)		10/11/201613/09/2016A Long-Acting Growth Hormone (Somavaratan, VRS-317) in ChildrenAn Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children with Growth Hormone DeficiencyThe VISTA Study: Versartis Long-Term Safety Study of Somavaratan Growth hormone deficiency
MedDRA version: 20.0;Level: PT;Classification code 10056438;Term: Growth hormone deficiency;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]		Product Name: Somavaratan
Product Code: VRS-317
INN or Proposed INN: VRS-317
Other descriptive name: VRS-317		Versartis, Inc.NULLNot RecruitingFemale: yes
Male: yes		400Phase 3United States;Canada;Poland;Belgium;Sweden
5EUCTR2014-004525-41-PL
(EUCTR)		09/03/201623/02/2016A Long-Acting Growth Hormone (Somavaratan, VRS-317) in Children compared to Daily rhGH.Comparison of Somavaratan (VRS-317), a Long-acting Human Growth Hormone, to Daily rhGH in a Phase 3, Randomized, One-year, Open-label, Multi-center, Non-inferiority Trial in Pre-pubertal Children with Growth Hormone Deficiency. - VELOCITY Growth hormone deficiency
MedDRA version: 20.0;Level: PT;Classification code 10056438;Term: Growth hormone deficiency;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]		Product Name: VRS-317
INN or Proposed INN: VRS-317
Other descriptive name: VRS-317
INN or Proposed INN: Recombinant human growth hormone
Other descriptive name: RECOMBINANT HUMAN GROWTH HORMONE		Versartis, Inc.NULLNot RecruitingFemale: yes
Male: yes		136Phase 3United States;Canada;Belgium;Poland;Netherlands;Sweden
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6NCT02719990
(ClinicalTrials.gov)		February 9, 201616/3/2016Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in AGHDAn Open-Label, Long-Term Extension Study of the Safety of Somavaratan (VRS-317) in Adults With Growth Hormone Deficiency (GHD)Adult Growth Hormone Deficiency (AGHD)Drug: somavaratanVersartis Inc.Premier Research Group plcTerminated18 Years75 YearsAll34Phase 2Australia;United States
7EUCTR2015-002072-24-DE
(EUCTR)		22/10/201512/08/2015A Long Acting Growth Hormone (Somavaratan) clinical study in adults to determine effective dose.An Open-Label, Dose Finding, International Phase 2 Study with Once Monthly Subcutaneous Somavaratan (VRS-317) in Adult Growth Hormone Deficiency (GHD)Versartis International Trial in Adults with Long Acting Growth Hormone. The VITAL study - Versartis International Trial in Adults with Long Acting Growth Hormone (VITAL) Growth Hormone Deficiency in adults
MedDRA version: 18.1;Level: PT;Classification code 10056438;Term: Growth hormone deficiency;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]		Product Name: Somavaratan
Product Code: VRS-317
INN or Proposed INN: Somavaratan
Other descriptive name: VRS-317		Versartis Inc.NULLNot RecruitingFemale: yes
Male: yes		40Phase 2United States;Australia;Germany;United Kingdom
8NCT02339090
(ClinicalTrials.gov)		August 24, 20157/1/2015Versartis Long-Acting Growth Hormone in Children Compared to Daily rhGHComparison of Somavaratan (VRS-317), a Long-acting Human Growth Hormone, to Daily rhGH in a Phase 3, Randomized, One-year, Open-label, Multi-center, Non-inferiority Trial in Pre-pubertal Children With Growth Hormone Deficiency.Growth DisordersDrug: somavaratan;Drug: Daily rhGHVersartis Inc.NULLCompleted3 Years11 YearsAll136Phase 3Belgium;Canada;Netherlands;Poland;Sweden;United States
9NCT02413138
(ClinicalTrials.gov)		August 8, 201523/3/2015Versartis Trial in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD) to Assess Long-Acting Growth Hormone (Somavaratan, VRS-317)A Randomized, Phase 2/3, Open-Label, Multi-center Study of the Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of A Long-acting Human Growth Hormone (Somavaratan, VRS-317) in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD)Pediatric Growth Hormone Deficiency;Growth DisordersDrug: Somavaratan (VRS-317)Versartis Inc.NULLTerminated3 Years10 YearsAll41Phase 2;Phase 3Japan
10EUCTR2014-004525-41-BE
(EUCTR)		22/04/201516/02/2015A Long-Acting Growth Hormone (Somavaratan, VRS-317) in Children compared to Daily rhGHComparison of Somavaratan (VRS-317), a Long-acting Human Growth Hormone, to Daily rhGH in a Phase 3, Randomized, One-year, Open-label, Multi-center, Non-inferiority Trial in Pre-pubertal Children with Growth Hormone Deficiency. - VELOCITY Growth hormone deficiency
MedDRA version: 19.0;Level: PT;Classification code 10056438;Term: Growth hormone deficiency;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]		Product Name: VRS-317
INN or Proposed INN: VRS-317
Other descriptive name: VRS-317
INN or Proposed INN: Recombinant human growth hormone
Other descriptive name: RECOMBINANT HUMAN GROWTH HORMONE		Versartis, Inc.NULLNot RecruitingFemale: yes
Male: yes		136Phase 3United States;Canada;Poland;Belgium;Netherlands;Sweden
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
11EUCTR2014-004525-41-SE
(EUCTR)		10/04/201512/02/2015A Long-Acting Growth Hormone, Somavaratan (VRS-317), in Children compared to Daily rhGHComparison of Somavaratan (VRS-317), a Long-acting Human Growth Hormone, to Daily rhGH in a Phase 3, Randomized, One-year, Open-label, Multi-center, Non-inferiority Trial in Pre-pubertal Children with Growth Hormone Deficiency. - VELOCITY Growth hormone deficiency
MedDRA version: 19.0;Level: PT;Classification code 10056438;Term: Growth hormone deficiency;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]		Product Name: Somavaratan (VRS-317)
INN or Proposed INN: VRS-317
Other descriptive name: VRS-317
INN or Proposed INN: Recombinat human growth hormone
Other descriptive name: RECOMBINANT HUMAN GROWTH HORMONE		Versartis, Inc.NULLNot RecruitingFemale: yes
Male: yes		136Phase 3United States;Canada;Poland;Belgium;Netherlands;Sweden
12NCT02068521
(ClinicalTrials.gov)		March 3, 20146/2/2014Versartis Long-Term Safety Study of SomavaratanAn Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone DeficiencyPediatric Growth Hormone DeficiencyDrug: somavaratanVersartis Inc.NULLTerminated3 YearsN/AAll385Phase 2;Phase 3United States

Back to top